Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20025753 | 0.88 | KDM1A (0.50) | KDM1A | |
| SCHEMBL20594901 | 0.85 | KDM1A (0.43) | KDM1A | |
| SCHEMBL20595087 | 0.85 | KDM1A (0.44) | KDM1A | |
| SCHEMBL19066238 | 0.84 | KDM1A (0.67) | KDM1A | |
| SCHEMBL20673172 | 0.81 | KDM1A (0.53) | KDM1A | |
| SCHEMBL20657198 | 0.80 | KDM1A (0.60) | KDM1A | |
| SCHEMBL20595107 | 0.80 | KDM1A (0.57) | KDM1A | |
| SCHEMBL20595133 | 0.80 | KDM1A (0.62) | KDM1A | |
| SCHEMBL20595132 | 0.80 | KDM1A (0.62) | KDM1A | |
| SCHEMBL19095361 | 0.79 | KDM1A (0.47) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219689-A2 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-3397756-B1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| EP-3423443-B1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| CN-111032641-A | Substituted 5-cyanoindole compounds and uses thereof | 诺华股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-10590079-B2 | Cyano-substituted indoles as LSD1 inhibitors | NOVARTIS AG (CH) | 2020-03-17 | — | — | US | disclosed |
| CN-110582488-A | Immune effector cell therapy with enhanced efficacy | 诺华股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CL) | 2019-10-03 | — | — | US | disclosed |
| EP-3523290-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2019-08-14 | — | — | EP | disclosed |
| US-20190092724-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2019-03-28 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| US-20190000880-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2019-01-03 | — | — | US | disclosed |
| EP-3397756-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2018-11-07 | — | — | EP | disclosed |
| WO-2018059549-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018059549-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2018-04-05 | — | — | WO | disclosed |
| WO-2017114497-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017114497-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | KDM1B, KDM1A, KDM2A | KDM1A 2/4885 |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | KDM1A, KDM5A, KDM1B | KDM1A 1/4885 |
| US-10590079-B2 | Cyano-substituted indoles as LSD1 inhibitors | KDM1A, KDM1B, KDM3A | KDM1A 1/4885 |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | KDM1A, KDM5A, KDM1B | KDM1A 1/4885 |
| US-20190092724-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM2A | KDM1A 1/4885 |
| US-20190000880-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | KDM1B, KDM1A, KDM2A | KDM1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.